People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Biotechnology, Medical Devices
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Quellis Biosciences, Inc. | — | Biotechnology | Series A | $13.1M | $29.7M | 2018 |
| CereVasc, Inc. | — | Biotechnology | Series A | $11.1M | $399.6M | 2020 |
| Juno Diagnostics, Inc. | — | Medical Devices | Series A | $6.3M | $107.9M | 2021 |
| PolyCore Therapeutics, Inc. | — | Biotechnology | Series A | $4.7M | $78.2M | 2022 |
Frederick Callori at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Frederick Callori on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chris Garabedian | 3 | 8 |
| Patrick Sullivan | 1 | 7 |
| Jonathan Violin | 1 | 5 |
| Peter Harwin | 1 | 4 |
| Tomas Kiselak | 1 | 3 |
| Dirk Van Den Boom | 1 | 2 |
| Christopher Garabedian | 1 | 2 |
| Daniel Levangie | 1 | 1 |
| Leslie Teso-Lichtman | 1 | 1 |
| Christopher B. Cashman | 1 | 1 |
| Kelly Beck | 1 | 1 |
| James B. Harris | 1 | 1 |
| Jim Chauvapun | 1 | 1 |
| Aaron Levangie | 1 | 1 |
| Carl Heilman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.